{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:08:05Z","timestamp":1779314885595,"version":"3.51.4"},"reference-count":65,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221413"],"award-info":[{"award-number":["BK20221413"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231374"],"award-info":[{"award-number":["BK20231374"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930058"],"award-info":[{"award-number":["81930058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341032"],"award-info":[{"award-number":["82341032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research and Development Program of China","award":["2022YFC250440"],"award-info":[{"award-number":["2022YFC250440"]}]},{"name":"Research and Development Program of China","award":["2023YFC2605104"],"award-info":[{"award-number":["2023YFC2605104"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,7]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To systematically compare the effects of various antithrombotic strategies on prespecified outcomes including 28-day all-cause mortality (primary outcome), major thrombotic events and major bleeding events (secondary outcomes) in adult COVID-19 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Systematic review and Bayesian network meta-analysis (NMA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>PubMed, Web of Science, Embase, Cochrane Library and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link> up to February 2024.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria<\/jats:title>\n                  <jats:p>We included randomised controlled trials (RCTs; published in English) comparing different antithrombotic strategies (eg, anticoagulants, antiplatelet (AP) agents, fibrinolytics or combinations) in adults (aged\u226518 years) with laboratory-confirmed SARS-CoV-2 infection. Eligible trials had at least one active antithrombotic arm versus another strategy or standard care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data extraction and synthesis<\/jats:title>\n                  <jats:p>Two reviewers independently extracted data using a standardised form; disagreements were resolved by consensus or third-party adjudication. Bayesian NMA was performed using Markov chain Monte Carlo methods with random\/fixed effects models selected by the deviance information criterion. The risk of bias (RoB) was assessed using the Cochrane Collaboration\u2019s tool. The confidence in NMA framework was used to assess the quality of evidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>35 RCTs that randomly assigned 39\u2009949 participants were included in the main analysis. Primary outcome: evidence of low to moderate certainty suggested that, compared with standard of care (SoC), both prophylactic-dose anticoagulation (PA) (risk ratio (RR) 0.71, 95% credible interval (CrI) 0.44 to 0.99) and therapeutic-dose anticoagulation (TA; RR 0.65, 95% CrI 0.38 to 0.94) reduced the 28-day all-cause mortality. Secondary outcomes: TA (RR 0.19, 95% CrI 0.09 to 0.31), TA+AP (RR 0.27, 95% CrI 0.05 to 0.95), PA (RR 0.33, 95% CrI 0.18 to 0.53) and AP+PA (RR 0.52, 95% CrI 0.25 to 0.94) were effective in reducing major thrombotic events. AP was associated with an increased risk of major bleeding events (RR 2.27, 95% CrI 1.01 to 5.07). Subgroup analyses by hospitalisation status showed that PA significantly reduced 28-day mortality versus SoC (RR 0.52, 95% CrI 0.26 to 0.90) for non-hospitalised patients, whereas no strategies showed significant benefit in hospitalised patients. Subgroup analysis based on severity of hospitalised patients indicated that TA was more favourable than PA in decreasing the 28-day mortality in non-critically ill patients (fixed-effect model: RR 0.75, 95%\u2009CI 0.61 to 0.91; random-effect model: RR 0.71, 95%\u2009CI 0.48 to 1.05), but for critically ill patients, all antithrombotic strategies showed no significant difference.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our NMA indicates that both PA and TA reduced the 28-day all-cause mortality of adult COVID-19 patients. However, subgroup analyses revealed substantial heterogeneity, and the benefit may differ across hospitalisation status and disease severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022355213.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088917","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:40:19Z","timestamp":1756824019000},"page":"e088917","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic strategies in adult COVID-19 patients: a systematic review and Bayesian network meta-analysis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04391179","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04424901","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04504032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04505592","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04391179","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04424901","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04504032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04505592","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-8719","authenticated-orcid":false,"given":"Han-Bing","family":"Chen","sequence":"first","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-4929","authenticated-orcid":false,"given":"Jing-Yuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Shi","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chi","sequence":"additional","affiliation":[{"name":"Key Laboratories of Enteric Pathogenic Microbiology (Ministry of Health), Nanjing, Jiangsu, China"},{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yue","family":"Ge","sequence":"additional","affiliation":[{"name":"Key Laboratories of Enteric Pathogenic Microbiology (Ministry of Health), Nanjing, Jiangsu, China"},{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lun-Biao","family":"Cui","sequence":"additional","affiliation":[{"name":"Key Laboratories of Enteric Pathogenic Microbiology (Ministry of Health), Nanjing, Jiangsu, China"},{"name":"Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5972-6733","authenticated-orcid":false,"given":"Shi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"},{"name":"Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-9172","authenticated-orcid":false,"given":"Jianfeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-4717","authenticated-orcid":false,"given":"Haibo","family":"Qiu","sequence":"additional","affiliation":[{"name":"Jiangsu Provincial Key Laboratory of Critical Care Medicine, Nanjing, Jiangsu, China"},{"name":"Department of Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2025100512101182000_15.9.e088917.1","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/jth.14975","article-title":"Coagulopathy in COVID-19","volume":"18","author":"Iba","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025100512101182000_15.9.e088917.2","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.14657"},{"key":"2025100512101182000_15.9.e088917.3","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.numecd.2020.07.040","article-title":"Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity","volume":"30","author":"Gazzaruso","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025100512101182000_15.9.e088917.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study","volume":"377","author":"Katsoularis","year":"2022","journal-title":"BMJ"},{"key":"2025100512101182000_15.9.e088917.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13072"},{"key":"2025100512101182000_15.9.e088917.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4152"},{"key":"2025100512101182000_15.9.e088917.7","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/jth.14828","article-title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025100512101182000_15.9.e088917.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12575-021-00142-y","article-title":"Anatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of Death","volume":"23","author":"Chen","year":"2021","journal-title":"Biol Proced Online"},{"key":"2025100512101182000_15.9.e088917.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006520"},{"key":"2025100512101182000_15.9.e088917.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105911"},{"key":"2025100512101182000_15.9.e088917.11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"2025100512101182000_15.9.e088917.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.17272"},{"key":"2025100512101182000_15.9.e088917.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103417"},{"key":"2025100512101182000_15.9.e088917.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02392-8"},{"key":"2025100512101182000_15.9.e088917.15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"The Lancet"},{"key":"2025100512101182000_15.9.e088917.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"2025100512101182000_15.9.e088917.17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2024.04.007","article-title":"Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis","volume":"238","author":"Reis","year":"2024","journal-title":"Thromb Res"},{"key":"2025100512101182000_15.9.e088917.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.698008","article-title":"A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients","volume":"12","author":"Giossi","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025100512101182000_15.9.e088917.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-022-00408-9","article-title":"Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis","volume":"20","author":"Duo","year":"2022","journal-title":"Thromb J"},{"key":"2025100512101182000_15.9.e088917.20","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"2025100512101182000_15.9.e088917.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025100512101182000_15.9.e088917.22","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025100512101182000_15.9.e088917.23","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"2025100512101182000_15.9.e088917.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"2025100512101182000_15.9.e088917.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2025100512101182000_15.9.e088917.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2025100512101182000_15.9.e088917.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025100512101182000_15.9.e088917.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab813"},{"key":"2025100512101182000_15.9.e088917.29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102004","article-title":"Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial","volume":"60","author":"Avezum","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025100512101182000_15.9.e088917.30","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00175-2"},{"key":"2025100512101182000_15.9.e088917.31","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.chest.2021.09.024","article-title":"Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial [J]","volume":"161","author":"Barrett","year":"2022","journal-title":"Chest"},{"key":"2025100512101182000_15.9.e088917.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14428","article-title":"Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial","volume":"6","author":"Berger","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025100512101182000_15.9.e088917.33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT","volume":"146","author":"Bohula","year":"2022","journal-title":"Circulation"},{"key":"2025100512101182000_15.9.e088917.34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00173-9"},{"key":"2025100512101182000_15.9.e088917.35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00299-5"},{"key":"2025100512101182000_15.9.e088917.36","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00298-3"},{"key":"2025100512101182000_15.9.e088917.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-022-07570-5","article-title":"Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)","volume":"22","author":"Ghati","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025100512101182000_15.9.e088917.38","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial","volume":"121","author":"Gonzalez-Ochoa","year":"2021","journal-title":"Thromb Haemost"},{"key":"2025100512101182000_15.9.e088917.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.09.026"},{"key":"2025100512101182000_15.9.e088917.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01203-4"},{"key":"2025100512101182000_15.9.e088917.41","doi-asserted-by":"publisher","DOI":"10.1055\/a-1667-7534"},{"key":"2025100512101182000_15.9.e088917.42","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13735","article-title":"Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial","volume":"52","author":"Morici","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2025100512101182000_15.9.e088917.43","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15450"},{"key":"2025100512101182000_15.9.e088917.44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.063901"},{"key":"2025100512101182000_15.9.e088917.45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2021.12.003","article-title":"Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial","volume":"216","author":"Rashidi","year":"2022","journal-title":"Thromb Res"},{"key":"2025100512101182000_15.9.e088917.46","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00392-023-02240-1","article-title":"Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial","volume":"112","author":"Rauch-Kr\u00f6hnert","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2025100512101182000_15.9.e088917.47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2910"},{"key":"2025100512101182000_15.9.e088917.48","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025100512101182000_15.9.e088917.49","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2023.02.041","article-title":"Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19","volume":"81","author":"Stone","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025100512101182000_15.9.e088917.50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/M22-3350","article-title":"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization","volume":"176","author":"Wang","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025100512101182000_15.9.e088917.51","unstructured":"Knight J S . Dipyridamole to prevent coronavirus exacerbation of respiratory status (DICER) in COVID-19. Clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04391179 [Accessed 30 Jan 2024]."},{"key":"2025100512101182000_15.9.e088917.52","unstructured":"Liang B . Trial of open label dipyridamole in hospitalized patients with COVID-19 (TOLD). Clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04424901 [Accessed 30 Jan 2024]."},{"key":"2025100512101182000_15.9.e088917.53","unstructured":"Institute B M G M R . A trial to evaluate safety and efficacy of rivaroxaban (COVID-19). Clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04504032 [Accessed 30 Jan 2024]."},{"key":"2025100512101182000_15.9.e088917.54","unstructured":"Poor H . Tenecteplase in patients with COVID-19 . Clinicaltrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505592 [Accessed 30 Jan 2024]."},{"key":"2025100512101182000_15.9.e088917.55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102451","article-title":"Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19: A systematic review and meta-analysis","volume":"49","author":"Ansari","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2025100512101182000_15.9.e088917.56","doi-asserted-by":"crossref","DOI":"10.1177\/10760296231191123","article-title":"Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis","volume":"29","author":"Hafiz","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025100512101182000_15.9.e088917.57","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.3390\/jcm10235549","article-title":"High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis","volume":"10","author":"Kollias","year":"2021","journal-title":"JCM"},{"key":"2025100512101182000_15.9.e088917.58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.3651"},{"key":"2025100512101182000_15.9.e088917.59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11239-022-02681-x","article-title":"Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials","volume":"54","author":"Pilia","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"2025100512101182000_15.9.e088917.60","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-018-0925-6","article-title":"Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury","volume":"19","author":"Mu","year":"2018","journal-title":"Respir Res"},{"key":"2025100512101182000_15.9.e088917.61","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817"},{"key":"2025100512101182000_15.9.e088917.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062-x"},{"key":"2025100512101182000_15.9.e088917.63","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/rth2.12353","article-title":"Using heparin molecules to manage COVID-2019","volume":"4","author":"Liu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2025100512101182000_15.9.e088917.64","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1016\/j.jtha.2024.06.009","article-title":"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19","volume":"22","author":"Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2025100512101182000_15.9.e088917.65","unstructured":"COVID-19 Treatment Guidelines Panel . Antithrombotic therapy in patients with COVID-19. National Institutes of Health. Available: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antithrombotic-therapy\/ [Accessed 30 Jan 2024]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:10:35Z","timestamp":1759691435000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2024-088917"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088917","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}